Consistent with this, our flow cytometry analysis of tumor-infiltrating lymphocytes showed that there were significantly more CD4+, CD8+ T cells, and NK cells in the tumors of the rAAV-P2 treatment group than those compared to the control group (Fig. 4h). The gene discussed is CD8A; the disease is neoplasm.